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Gemcitabine is a potent nucleoside analogue against solid tumors however
drug resistance rapidly emerges. Removal of gemcitabine incorporated in the DNA
by repair mechanisms could potentially contribute to resistance in chemo-refractory
solid tumors. In this study, we evaluated homologous recombination repair of
gemcitabine-stalled replication forks as a potential mechanism contributing to
resistance. We also studied the effect of hyperthermia on homologous
recombination pathway to explain the previously reported synergy between
gemcitabine and hyperthermia. We found that hyperthermia degrades and inhibits
localization of Mre11 to gemcitabine-stalled replication forks. Furthermore,
gemcitabine-treated cells that were also treated with hyperthermia demonstrate a
prolonged passage through late S/ G2 phase of cell cycle in comparison to cells
treated with gemcitabine alone. This coincides with inhibition of resolution of γH2AX
foci. Our findings also demonstrate that thermal sensitization of human
hepatocellular carcinoma cell lines to gemcitabine is mediated through an Mre11dependent homologous recombination repair pathway. Combination of non-invasive
radiofrequency field-induced hyperthermia and gemcitabine was superior to either
therapy alone (p<0.05) in two different orthotopic murine models of hepatocellular
carcinoma. This study provides mechanistic understanding and support of
homologous

recombination

inhibiting-strategies,

such

as

non-invasive

radiofrequency field-induced hyperthermia, to overcome resistance to gemcitabine
in refractory human solid tumors.
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1. INTRODUCTION

1.1 Hepatocellular carcinoma – an emerging health problem
Primary hepatocellular carcinoma (HCC) is an aggressive disease. Globally,
about one million new cases of HCC are diagnosed each year with an identical
cause-specific mortality rate demonstrating a very high case fatality rate. It is the
fifth most common cause of cancer death in men and the ninth most common cause
of cancer death in women (1, 2). Invariably, HCC is associated with underlying liver
cirrhosis, chronic inflammation and/or infection. About 80% of the patients have
chronic Hepatitis B or C infection (3). The incidence of HCC varies across
geographic locations, predominantly because of variations in prevalence of
Hepatitis B and C infection, alcohol consumption as well as aflatoxin exposure.
In the United States, the incidence of HCC is relatively low with an estimated
occurrence of 3.2 per 100,000 (4, 5). It is estimated that approximately 28,000 new
cases of HCC will be diagnosed in 2012 with approximately 20,000 deaths (NCI).
However, this incidence is gradually rising and is expected to increase in the
coming years (4, 5). The rising incidence can be attributed to an aging population,
immigrating population from East Asia, non-alcoholic steatohepatitis and a high
incidence of hepatitis C from 1960 to 1990 (with a lag time of 20-30 years).
Important demographic differences exist between different parts of the world in
regards to HCC. For instance, the average age at the time of presentation in subSaharan Africa is 33 years while in the rest of the world it is 50 to 60 years (2, 6). In
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U.S. the most common risk factors for the development of HCC are hepatitis C
infection (5), hepatitis B infection (7),alcohol use and non-alcoholic steatohepatitis
(8). In addition to these risk factors, exposure to environmental toxins such as
aflatoxin (9), betel nut (10) and contaminated water containing microcystin (11) is
commonly observed in East Asia and parts of Africa. A recent study examining a
large cohort demonstrated a significant association between saturated fat or red
meat consumption and liver cancer (12). In separate studies, type 2 diabetes and
metabolic syndrome have been associated with liver cancer (13, 14). This
predisposition may be due to underlying non-alcoholic steatohepatitis.
At presentation, patients usually have either advanced liver cancer, liver
dysfunction or both. Signs and symptoms develop late in the course of the disease
and are mostly indistinguishable from those of underlying liver dysfunction (15).
Because of delayed diagnosis, the median survival of untreated advanced liver
cancer is 6 to 20 months (16). Most patients die from local disease with
uncompensated liver failure as the initiating event.

1.2 Current treatment strategies
The mainstay of curative therapy for patients with HCC is surgical resection
(17). The majority of patients at presentation, however, are not eligible for surgery
because of underlying liver dysfunction.

In early stage HCC (as defined by

Milano/Mazzaferro criteria (18)) with poor liver function, liver transplantation is the
preferred option. Patients needing liver transplantation are prioritized according to
MELD score (19). Even though patients with HCC receive a higher MELD score, the
gap between organ demand and supply may require a lag time of several months.

2
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Under these circumstances bridging therapies are often employed with trans-arterial
chemoembolization (TACE) being the most common (20). For patients who do not
meet the criteria for resection or transplantation but have localized disease, a
multitude of local-regional therapies can be used based on availability and local
expertise.

These

include

percutaneous

ethanol

or

acetic

acid

ablation,

radiofrequency or microwave ablation, radiotherapy, bland microspheres or radio
therapeutic microspheres (21). Patients eligible for these local-regional therapies
including resection or transplantation constitute less than 25% of patients diagnosed
with HCC. For the remaining 75% of patients therapeutic options are limited.
For patients with multifocal, unresectable or metastatic HCC, systemic
therapy is usually recommended. Conventional cytotoxic therapy has been shown
to be of minimal benefit in these patients for multiple reasons. Most importantly,
HCC is considered a chemo-refractory tumor with high expression of drug
resistance genes products including P-glycoprotein, heat shock proteins and
mutated tumor suppressor p53 protein (22-24). Patients with HCC do not tolerate
chemotherapy well because of underlying liver dysfunction. Since most patients with
HCC succumb to their hepatic dysfunction, this limits our ability to study
effectiveness of chemotherapy in the context of a clinical trial. Recently however, a
multi-kinase inhibitor, sorafenib showed a modest improvement in median overall
survival of approximately 3 months making it the new standard of care (25). While
this clinical response of a molecularly targeted therapy is encouraging, the benefit
afforded to these patients is transient. A major challenge therefore remains in

3
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understanding drug resistance pathways in HCC and exploiting them for developing
better therapies.
1.3 Gemcitabine and resistance mechanisms
1.3.1. Clinical use of gemcitabine as a single agent in advanced HCC: Like
most other cytotoxic chemotherapies, gemcitabine has shown minimal benefit in
patients with advanced HCC. In one phase II study, 28 previously untreated
Taiwanese patients with advanced liver cancer not amenable to local-regional
therapies received single agent gemcitabine therapy at 1250mg/m2/wk (26). An
overall response rate of 17.8% (95% CI, 2.7-32.9%) was noted. There were no
complete responses, 25% had stable disease and 57.2% had disease progression.
Most patients progressed within 12 weeks of the start of therapy. The authors
concluded that the toxicity of gemcitabine was minimal and favor its use despite
short-lived benefit. Contrary to these findings, a study on 20 European patients
using a similar regimen demonstrated a much lower partial response rate of 5%
(27). Confirming the findings of this study a high-dose gemcitabine regimen in 17
European patients failed to yield any objective response. However, stable disease
was noted in 47% of patients during the course of therapy (28). In a follow-up study
conducted in the USA, 30 patients with advanced HCC received single-agent
gemcitabine at 1000mg/m2/wk. Again, no responses were observed, but 30% of
patients had stable disease (29). Fixed-dose rate regimens yield higher intracellular
drug concentrations with comparable toxicity to single-bolus regimens in several
other solid tumors and may be more effective (30). This regimen was tested in a
phase II study where a similar cohort of 50 Asian patients was randomized to

4
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receive gemcitabine as a single agent, either as a bolus or on a fixed-dose rate
regimen. The authors noted that there was only one partial response in the fixeddose rate arm with an overall response rate of 2.1% (31). Except one study from
Taiwan, all studies demonstrate that gemcitabine even though well tolerated, is
ineffective as a single agent in advanced liver cancer regardless of the dose or
regimen used.
1.3.2. Clinical use of gemcitabine as combination therapy in advanced HCC:
Several combination regimens consisting of gemcitabine have been used with more
encouraging results. Most often gemcitabine has been combined with platinumbased chemotherapy. For instance, a phase II study comprising 34 previously
untreated patients with advanced HCC who received gemcitabine and cisplatin
demonstrated an overall response rate of 18% (95% CI 8-34%). Most patients
(58%) had stable disease. This regimen was also well tolerated despite hepatic
dysfunction (32). In a comparable study of 30 patients that employed cisplatin in
place of oxaliplatin, a response rate of 20% was observed with stable disease in
43% of the patients (33). In a more recent study bevacizumab, a monoclonal
antibody against vascular endothelial growth factor was added to a gemcitabine and
oxaliplatin regimen. A response rate similar to prior studies of about 20% was
reported, suggesting no added benefit from bevacizumab (34). Gemcitabine has
also been used in combination with doxorubicin (35). However in 50 patients
evaluated, there was a partial response rate of only 11.4% with stable disease in
44% of the patients. Data from these studies demonstrate that gemcitabine is well
tolerated but combination therapies are only slightly more effective in comparison to

5
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single-agent gemcitabine therapy. Moreover, the response rates are low and the
benefit is transient, underscoring the need to understand resistance mechanisms to
these therapies for better approaches to higher and more sustained responses and
ultimately to improve median survival.
1.3.1. Mechanism of action and resistance: Gemcitabine (2’, 2’ - difluoro 2’ deoxycytidine, dFdC) is nucleoside analogue that is similar to deoxycytosine and is
structurally related to its predecessor Ara-C (arabinoside cytosine) that showed
potent activity in hematologic malignancies. It is a pro-drug that requires transport
into the cells before activation and incorporation. Gemcitabine is taken up by the
cells via human nucleotide transporters (hNTs) on the cell membrane (36). Upon
internalization, it is phosphorylated by deoxycytidine kinase (dCK) to produce
gemcitabine

mono-phosphate

(dFdCMP),

di-phosphate

(dFdCDP)

and

tri-

phosphate (dFdCTP) in sequential steps (37). Gemcitabine tri-phosphate is the
active drug that is incorporated into the DNA or RNA. Once incorporated into the
leading and lagging strand of the DNA during replication, gemcitabine allows
incorporation of one additional nucleotide before chain termination (38). This
phenomenon called masked chain termination is unique to gemcitabine and is
believed to be important in its evasion of excision enzymes. Gemcitabine triphosphate has several self-potentiating mechanisms that enhance its cytotoxicity by
increasing incorporation into the DNA. For instance, dFdCTP inhibits deoxycytidine
mono-phosphate deaminase (dCDA), preventing the degradation of its precursor,
dFdCMP (39). More importantly dFdCDP is a potent inhibitor of ribonucleotide
reductase (RR), an enzyme required for conversion of nucleotide tri-phosphates

6
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(NTPs) into deoxy-NTPs (dNTPs) (40). By inhibiting dNTP synthesis, gemcitabine
decreases competition against its incorporation into the DNA. The mechanisms that
lead to cell death after incorporation of gemcitabine in the DNA remain elusive,
however, apoptosis has been implicated in certain cell types.
Study of gemcitabine resistance has focused on pathways involving its
transport and metabolism or those of apoptosis and survival. In vitro studies have
demonstrated that cells deficient in equilibrative type nucleotide transporter 1
(hENT1) are highly resistant to gemcitabine (36). This observation is consistent with
data from patients where hENT1 expression levels correlate with gemcitabine
sensitivity (37). Since, gemcitabine needs to be phosphorylated to become active, it
is not surprising to note that lack of dCK activity correlates with resistance to
gemcitabine (37). Conversely, a higher expression of dCDA in mononuclear cells
was associated with resistance to gemcitabine in a cohort of pancreatic cancer
patients (41). Additionally, nucleotidase 1 (5’ NT-1) plays an important role in
dephosphorylating dFdCTP and its over expression has also been associated with
lower activity of gemcitabine in several cell lines (42). The most important selfpotentiation

mechanism

responsible

for

sustained

effective

intracellular

concentration of gemcitabine is inhibition of RR (40). In non-small cell lung cancer
cell lines and patients, over expression of RR sub-unit 1 (RRM1) was associated
with gemcitabine resistance and a worse survival (43-46). RR sub-unit 2 (RRM2)
modulates RRM1 enzymatic activity. Expectedly, over expression of RRM2 also
contributes to gemcitabine resistance (47). Various pro-survival cell-signaling
pathways that are associated with gemcitabine resistance in cell lines or animal
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models involve phosphatidylinositol 3-kinase/ Akt pathway (48, 49), increased
activation or over-expression of focal adhesion kinase (50), c-Src (51, 52) or c-Met
(53). Pathways that trigger apoptosis upon exposure to gemcitabine have also been
implicated in sensitivity to gemcitabine. For instance, over-expression of S100A4
inhibits gemcitabine-induced apoptosis by regulating the hypoxia-induced proapoptotic gene BNIP3 (54, 55). In addition, it has been shown that p53-deficient cell
lines fail to undergo apoptosis in response to gemcitabine in comparison to wildtype p53 counter parts (56-58). These findings demonstrate a multitude of pathways
that are now known to be involved in gemcitabine resistance/ sensitivity.
As yet not much is known about the molecules that detect gemcitabine
incorporation into the DNA. It is also unclear what mechanisms are at play in
repairing gemcitabine-stalled replication forks and if these mechanisms are
important in resistance to gemcitabine. Aberrant mismatched nucleotides are
removed from the DNA by 3’-5’ exonuclease activity of DNA polymerase  (59). It
was demonstrated that dFdCMP residues are difficult to excise from the DNA, inpart due to masked-chain termination in comparison with dCMP residues (60).
Mismatch repair (MMR) enzymes also repair DNA by removing single base
aberrancies. MMR-deficient colon cancer and endometrial cells were found to be
more resistant than MMR-proficient parental cell lines implicating MMR pathway in
repair of gemcitabine-incorporated DNA (61). Recently, the role of homologous
recombination repair (HRR) in restarting stalled replication forks has become
clearer. Along that line, Ewald et al. studied the role of Mre11-Rad50-Nbs1 (MRN)
complex in responding to gemcitabine-induced DNA damage (62). They found that

8
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gemcitabine sensitivity was enhanced in cells deficient in one of several
components of the pathway, namely, ataxia telangiectasia mutated (ATM), 3’-5’
exonuclease Mre11 and Rad50. These findings provide a platform to further study
the role of the HRR pathway in gemcitabine resistance.
1.4 Repair of mammalian stalled replication forks
Error-free replication is required to maintain genomic information with high
fidelity. In normal cells, spontaneous blocks in replication can occur and can either
lead to a stalled replication fork or a collapsed replication fork (63). A stalled
replication fork is an arrested fork that can be restarted at a later time. A collapsed
fork occurs when the replication machinery dissociates from the DNA or a double
strand break occurs. Collapse of a stalled replication fork occurs typically with
prolonged replication blocks (64). While the pathways of fork restart are well
characterized in prokaryotes, those pathways do not exist in eukaryotic species
raising the possibility of alternative pathways. Recent advances in the field have
demonstrated that replication-independent mechanisms are involved. This restart
requires regression of the fork into a chicken foot-structure (65). In most cases this
replication fork intermediate is sensed by poly (ADP-ribose) polymerase 1 (PARP1).
Poly-ADP ribose residues in association with the chromatin recruit Mre11, a 3’-5’
exonuclease, for DNA end processing (66). The DNA end processing is essential
for loading of Rad51 recombinase on the DNA that forms a RAD51 nucleoprotein
filament (67). This complex subsequently catalyzes sister chromatid homology
search and strand invasion to complete homologous recombination. This model

9
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explains the observations where fork restart has been observed without the need for
generating or occurrence of a double strand break (65).
Since cancer cells undergo proliferation at a faster rate under the influence of
oncogenes or lack of tumor suppressors, the occurrence of stalled replication forks
is also at a higher rate. Failure to restart stalled replication forks without loss or
alteration of genetic information is thought to be an important basis of origin of
mutations in cancer (as described by oncogene-induced stress model of genomic
instability) (68). However once the malignant transformation has occurred, cancer
cells may rely on DNA repair pathways such as HRR to propagate the mutated
genome. In support of that model, the most commonly mutated gene in cancer, p53,
has been shown to tightly regulate the HRR pathway through transcriptional
regulation of Rad51 (69-73). For instance, loss of p53 or mutations in the DNA
binding domain of p53, up regulate Rad51 expression, which in turn enhances
homology-directed repair. These findings highlight the importance of the HRR
pathway in maintenance of replication in cancer cells, perhaps more so than in
normal cells. The dependence of cancer cells on homology-directed repair can be
further enhanced by treatment with replication inhibitors. Many replication inhibitors
are already in use in the clinic including hydroxyurea and nucleoside analogues. It
has been clearly demonstrated that cells treated with replication inhibitors exhibit
pronounced activation of HRR and that this pathway is essential for survival during
recovery from stalled replication forks (67). The role of HRR in recovery from
nucleoside analogue-stalled replication forks has not been studied specifically. At
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least one report suggests localization of HRR pathway proteins to sites of
gemcitabine-stalled replication forks (62).
1.5 Thermolabile targets in homologous recombination pathway
Hyperthermia involves raising the temperature of cells, tissues or organs
above normal and has been used in the treatment of cancers for more than a
century. The earliest observations from Busch demonstrated regression of a
sarcoma by fever resulting from erysipelas (74). Later Coley purposely administered
the bacterial toxins from Streptococcus group A (etiological agent of erysipelas) to
reproduce these effects. A variety of cellular and biological processes in cancer
cells are preferentially affected by hyperthermia (41-43oC) that may explain the
effects observed by Coley. Of these, effects of hyperthermia on DNA replication and
repair have been of most interest and form the rational basis of synergy between
chemoradiation and hyperthermia.
The seminal observation that implicates the HRR pathway in hyperthermiarelated cell death was that cancer cells are most sensitive to hyperthermia during
late S and G2 phase of the cell cycle (75). This finding implied that hyperthermia
must affect proteins involved in synthesis of DNA and/ or DNA repair. Even though
the involvement of the HRR pathway in repair of stalled replication forks has only
recently become clear, the thermal effects on the proteins in this pathway have
already been observed in the context of DNA double strand break repair as
described below.
1.5.1 PARP-1 and hyperthermia: PARP-1 has various cellular functions
including modulation of chromatin, transcription and single-strand DNA repair.
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Recently, PARP-1 has been implicated in repair of hydroxyurea-stalled replication
forks as a sensor upstream of several repair proteins. It has been shown that
PARP-1 enzymatic activity is inhibited by hyperthermia (76, 77). This result is
mainly due to sumoylation and subsequent ubiquitination of PARP1 upon heat
shock. Degradation of PARP1 in this fashion is important in the transcriptional
regulation of heat shock protein 70. It was found that in heat shocked rat livers,
PARP-1 increases in the insoluble nuclear matrix fraction while it decreases from
the soluble fraction of the nucleus (76). This is associated with decreased PARP-1
enzymatic activity. The authors concluded that hyperthermia destabilizes PARP-1
and when denatured, PARP-1 has a higher affinity for the nuclear matrix.
1.5.2 MRN-complex and hyperthermia: This complex is composed of two
enzymes Rad50 and Mre11, and one protein with catalytic function Nbs1. These
proteins rapidly localize to ionizing radiation-induced double strand breaks where
this complex primarily performs DNA end processing before repair. Mre11 is the
main excision enzyme with 3’-5’ exonuclease activity as well as endonuclease
activity. Rad50 can phosphorylate Mre11 and enhance its exonuclease activity
while Nbs1 binding enhances endonucleolytic activities of Mre11. Several prior
studies have evaluated the effects of heat shock on the functions of the MRN
complex. Zhu et al. heated U-1 human melanoma cells and HeLa cells for 15 min at
45.5oC and noted translocation of MRN complexes from the nucleus to the
cytoplasm (78). This effect lasted 7 hours with only partial recovery of Mre11 and
Rad50 levels in the nucleus. A follow up study by the same group administered an
equitoxic thermal dose of 42.5oC for 2 hours and found similar patterns of
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translocation, however the translocation was enhanced by up to two-fold. It was
further shown that administering leptomycin B, an inhibitor of nuclear exporter
CRM1, inhibits this translocation suggesting involvement of an active process (79).
In a later study, the same group demonstrated that hyperthermia inhibits localization
of MRN complex proteins to sites of ionizing radiation-induced double strand breaks
and speculated that this may be related to heat-mediated conformational changes in
the structure of these proteins (80). The recovery of MRN complex foci took up to
48 hours after heat shock. A more recent study by the same group failed to show
that

the

translocation

of

MRN

complex

proteins

is

important

in

heat

radiosensitization but implicated thermal denaturation of Mre11 in lack of MRN
complex formation and subsequent heat radiosensitization (81). They further
demonstrated inhibition of 3’-5’ exonuclease activity of Mre11 and its increased
association with heat shock protein 70 providing evidence of thermal denaturation.
These findings implicate Mre11 to be the key target of heat radiosensitization.
1.5.3 BRCA proteins and hyperthermia: The role of BRCA2 in repair of
double strand breaks by HRR is well characterized where it mediates Rad51
nucleoprotein filament formation. The role of BRCA2 in repair of stalled replication
forks is more complex however. In addition to assisting homology-directed repair,
BRCA2 inhibits exonucleolytic degradation of nascent strands at stalled replication
forks and keeps end processing by Mre11 3’-5’ exonuclease in check (82).
Enhanced nucleolytic degradation by Mre11 in the absence of BRCA2 was found to
increase chromosomal aberrations without a decrease in survival in cancer cells.
Krawczyk et al., while investigating the effects of hyperthermia on HRR of double-

13

Copyright © 2012 Mustafa Raoof. All rights reserved.

strand breaks demonstrated that thermal radiosensitization is mediated through
thermal degradation of BRCA2 downstream of Mre11 (83). Contradictory to prior
reports, they found no effects on Mre11 or on the formation of MRN complex. This
result could be explained on the basis of lower thermal dose administered in these
experiments and may suggest that BRCA2 is more sensitive to thermal effects than
Mre11. Degradation of BRCA1 after heat shock has been reported, however, its role
in repair of stalled replication forks is uncertain (84).
1.6 Hypothesis and specific aims
The studies mentioned above demonstrate that the main cytotoxic effect of
gemcitabine is mediated through its incorporation into the DNA and subsequent
stalling of replication fork progression. It is also known that the HRR pathway is the
main pathway involved in the repair of stalled replication forks and component
proteins of this pathway have been shown to respond to gemcitabine-stalled
replication forks. Finally, a profound effect of mild to moderate hyperthermia on
several of the key components of the HRR pathway has been demonstrated.
It is not known, however, if HRR of stalled replication forks is a significant
mechanism that contributes to chemoresistance of gemcitabine. The effects of
hyperthermia on repair of stalled replication forks also remain to be elucidated.
We hypothesize that mild to moderate hyperthermia can inhibit
homologous recombination after gemcitabine-stalled replication forks by its
effects on key components of the HRR pathway, hence contributing to
chemosensitivity. Our specific aims are as follows:
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Specific aim 1: To identify thermo-labile proteins in the HRR pathway as putative
targets of thermal chemosensitization
Specific aim 2:

To assess gemcitabine chemosensitization by hyperthermia-

induced inhibition of HRR in hepatocellular carcinoma cell lines in vitro.
Specific aim 3: To assess anti-tumor activity of gemcitabine with and without noninvasive radiofrequency field-induced hyperthermia in murine orthotopic xenografts
of primary hepatocellular carcinoma.

15

Copyright © 2012 Mustafa Raoof. All rights reserved.

2. Materials and methods
2.1 Cell lines, reagents and transfection
2.1.1. Cell Culture: All cell lines (Hep3B, HepG2 and SNU449) were
purchased from American Type Culture Collection (ATCC, Manassas, VA) and
maintained according to the supplier’s protocol. Media i.e. RPMI-1640 (for SNU449)
or MEM (for HepG2 or Hep3B) was supplemented with 10% (v/v) fetal bovine
serum. Additional supplementation for Hep3B culture media was performed with
sodium pyruvate and non-essential amino acids. Cells were cultured in T-75 or T150 tissue culture flasks (Corning Inc., Corning, NY). For each cell line short
tandem repeat fingerprint was confirmed by the Cell Line Characterization Core
Service (M. D. Anderson Cancer Center, Houston, TX) within one year of all
experiments. All media and supplements were purchased from Gibco (Life
technologies, Grand Island, NY). The cells were passaged approximately every
three to five days before reaching confluency. Media was replaced every three
days.
2.1.2 Cell Counting: Before each experiment cells were counted. For
clonogenic viability assays cells were counted using a hemocytometer and trypan
blue staining as described in detail later. For all other assays, counting was
performed using a cellometer (Nexcelom Bioscience, Lawrence, MA). First, cells
were trypsinized, washed with and re-suspended in PBS. Approximately 20μl of cell
suspension was diluted 1:1 with trypan blue solution. Of the 40μl, 20μl was loaded
on a disposable counting chamber (Nexcelom Bioscience, Lawrence, MA). The
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chamber slide was placed in the cellometer and viable cell counts were noted. For
all experiments viability was recorded to be greater than 90%.
2.1.3 Reagents, antibodies and culture plates: All reagents were purchased
from Sigma Aldrich (Sigma-Aldrich Corp, St. Louis, MO) unless otherwise stated.
Phosphate buffered saline was acquired from the surgical oncology core media
facility (M.D. Anderson Cancer Center, Houston, TX). Bromodeoxyuridine (BrdU)
was purchased from BD (BD Pharmingen, San Diego, CA). All experimental setups
required 6-well or 12-well culture plates purchased from Corning Inc. (Corning, NY).
For fluorescence microscopy, the following primary antibodies were used;
rabbit anti-PAR (Trevigen, Gaithersburg, MD), rat anti-RPA32 (4E4, Cell Signaling,
Danvers, MA), rabbit anti-Mre11 (GenTex, San Antonio, TX), rabbit anti-rad51 (H92, Santa Cruz biotechnology, Santa Cruz, CA), mouse anti-γH2AX (UpstateMillipore, Billerica, MA), rat anti-BrdU (BU1/75[ICR1], Abcam, Cambridge, MA).
Primary antibodies were detected using the following secondary antibodies; Alex
Fluor 488 conjugated donkey anti-rat, Alex Fluor 546 conjugated donkey anti-mouse
and Alex Fluor 647 conjugated donkey anti-rabbit antibodies (Invitrogen, Grand
Island, NY).
For western blot analysis, the following antibodies were used; mouse antiPARP (Trevigen, Gaithersburg, MD), rabbit anti-NBS1 (Cell Signaling, Danvers,
MA), rabbit anti-Rad50 (Cell Signaling, Danvers, MA), rabbit anti-mre11 (Gentex,
San Antonio, TX), rabbit anti-rad51 (H-92, Santa Cruz biotechnology, Santa Cruz,
CA), mouse anti-p53 (DO-1, Santa Cruz biotechnology, Santa Cruz, CA), rabbit
anti-BRCA2 (Calbiochem, Billerica, MA). Primary antibodies were detected using
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HRP-linked

goat

anti-rabbit

or

goat

anti-mouse

antibodies

(Jackson

Immunoresearch, West Grove, PA)
For colorimetric-based immunohistochemistry, mouse anti-human Ki67
(M7240, Dako, Carpinteria, CA), rabbit anti-cleaved caspase 3 (Asp175, Cell
Signaling, Danvers, MA) and rabbit anti-LC3B (Cell Signaling, Danvers, MA) were
used
2.1.4 Transfection: Two transfections were performed. First, Hep3B and
HepG2 cells were transfected to express GFP and luciferase to facilitate in vivo
detection of xenografts. Renilla luciferase containing plasmid pRL-TK (Promega,
Madison, WI) was modified by adding a GFP sequence. This recombinant plasmid
was transfected into NIH 293T cells to generate a lentivirus vector containing the
plasmid. This lentivirus was then used to infect Hep3B and HepG2 cell lines.
GFP/Luc-transduced stable cells lines were obtained by sorting GFP-positive cells
using FACScan (BD biosciences, Boston, MA)
For generating an Mre11-knockdown cell line, we used GPIZ lentiviral
shRNA (Open biosystems, Lafayette, CO) according to the supplied protocol. In
order to generate lentivirus, Hep3B cells were tranfected in separate experiments
with three random clones from shRNA library against Mre11 or a control shRNA
together with a packaging plasmid (Trans-lentiviral packaging system, Open
biosystems, Lafayette, CO) using lipofectamine 2000 (Invitrogen, Life technologies,
Grand Island, NY). Approximately 72 hours later, cells were observed under a
microscope to express GFP, which is a marker of expression of shRNA against
Mre11. Relative mre11 knockdown was confirmed by western blot analysis.
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2.2 Protein electrophoresis and immunoblotting
Approximately 200,000 cells were plated in 60mm cell culture plates. Cells
formed sub-confluent monolayers. The cells were exposed to moderate
hyperthermia in an incubator at 42.5oC for 2 hours and cell lysates were prepared
for western blotting before and at 0, 1, 4 and 24-hours after hyperthermia exposure
to evaluate the relative levels of various proteins. For preparation of whole cell
lysates, media was removed and cells were washed with PBS. Cell lysis buffer
(150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50mM Tris,pH
8.0, one mini protease inhibitor/ 10ml tablet Rosche # 11 836 153001) was added
on ice and lysed cells were collected after gentle scraping and mixed on ice for
30min. The lysates were spun at 15000 RPM for 10 min at 4oC. The supernatant
was collected and stored at -80oC before electrophoresis.
Protein concentrations were measured using Bradford assay (Fischer
scientific, Pittsburgh, PA) with bovine serum albumin as the standard curve,
according to manufacturer’s instructions. The samples were loaded at 20-40 μg/
well in a gel using a denaturing sodium dodecyl sulphate- polyacrylamide gel
electrophoresis (SDS-PAGE) system. Electrophoresed proteins were transferred
onto a polyvinylidene fluoride (PVDF) membrane overnight on ice. The transferred
proteins were probed using a specific antibody against each protein of interest. The
primary antibody was detected using a horseradish peroxidase (HRP)-conjugated
secondary antibody. HRP-conjugated secondary antibody was detected using an
Amersham ECL detection system (GE Health Care Biosciences, Pittsburgh, PA).
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For BRCA 2 detection, cell lysates were prepared as for other proteins.
However, NuPAGE large protein blotting kit was used that utilizes a 3-8% trisacetate gradient gel allowing better resolution of larger proteins.
2.3 Immunocytochemistry
For immunocytochemistry assay, indirect immunofluorescence approach was
used. Circular #1.5 cover slips (Electron microscopy sciences, Hatfield, PA) were
placed in 12-well plates and sterilized using a 20-minute UV exposure. Cells from
an exponentially growing culture were counted and approximately 50,000 cells were
seeded in each well of a 12-well plate. Adherent sub-confluent monolayers were
observed growing on the cover slip 24 hours later. At this point cells were exposed
to various treatment conditions as described in the results section. At the end of
treatment, immunolabeling of proteins being studied was performed. Cells were
fixed, permeablized, blocked, labeled with primary antibody and then with
secondary antibody in consecutive steps. Between each step cells were washed
with PBS three times for 5 minutes each time on a leveled shaker at 50 RPM. Cells
were fixed with 1% paraformaldehyde in PBS (w/v) for 30 minutes. Permeablization
was performed using 0.3 % (v/v) Triton-100 and 0.125 % (w/v) CHAPS (3-[(3Cholamidopropyl) dimethylammonio]-1- propanesulfonate) dissolved in PBS for 15
minutes. Cells were blocked for 1-hour in a 3 % (w/v) bovine serum albumin and 1
% (v/v) normal goat serum. Primary and secondary antibodies were diluted in the
blocking buffer. Incubation with primary antibody was performed over night at 4oC.
Secondary antibody incubations were performed for 2 hours at room temperature.
At the end of immunolabeling, 4',6-diamidino-2-phenylindole, DAPI (Molecular
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probes, Eugene, OR) was used to counter stain DNA at 1:5000 dilution for 15
minutes. Cover slips were washed one more time with PBS and were mounted on
frosted glass slides (Fischer Scientific, Waltham, MA) using Dako mounting media
(Dako, Carpinteria, CA).
The slides were sealed with a conventional nail polish hardener and stored at
4oC until imaging. For confocal imaging Fluoview - FV1000 Olympus Confocal
Microscope (Center Valley, PA) was used. Images were acquired using a 60x
(NA1.6, oil) or 100x (NA1.3, oil) objective at an X-Y resolution of 100nm and a Zstack resolution of ~800nm. Samples were excited using an incident LD laser at
405nm (50mW, 5% power) for DAPI, 559nm (15mW, 20%) for Alex Fluor 546, and
635nm (20mW, 20% power) for Alex Fluor 647. Capture resolution was set at twice
the optical resolution and Kallman averaging was set at 2 for enhanced signal to
noise ratio. Images were acquired sequentially to minimize cross contamination
from multiple emission spectra. Exposure settings were set to maximize dynamic
range initially and then kept constant across multiple samples to allow quantitative
comparisons.
Acquired images were processed in Slidebook (version 5.0, Intelligent
Imaging Innovations, Inc., Denver, CO). Nuclei were identified using the DAPI
channel and the areas were converted to regions of interest (ROI). Signals in these
ROIs from other channels were used for colocalization analysis. Colocalization
thresholds were defined using control images from secondary antibody alone slides
such that less than 5% of the pixels exceeded this threshold. Pearson’s correlation
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was used as an index of colocalization of pixels with intensity above the background
threshold.
2.4 Clonogenic assays
Clonogenic assay estimates single-cell reproductive viability by measuring
the ability of a single cell to form a colony of 50 cells or more. Clonogenic assay in
this study was performed as described previously (85). Briefly, cancer cells from an
exponentially growing, sub-confluent culture were trypsinized and harvested.
Approximately 200 cells were counted and plated in each well of a 6-well plate.
Approximately 12 hours later the cells were adherent and treatment conditions were
introduced as described in the results section. After varying treatments, media was
replaced and cells were allowed 14 days to form colonies. Subsequently, the media
was aspirated and cells were washed with PBS once. Colonies were then fixed with
glutaraldehyde (6.0% v/v) and stained with crystal violet (0.5% w/v) for 30 minutes
on a leveled shaker at 50 RPM.

The fixation and staining solution was then

aspirated and the 6-well plates were air-dried after gentle rinsing with tap water. The
number of colonies in each well was counted using a colony counting grid. We
found that early passage HepG2 failed to form colonies using standard condition or
by using pre-conditioned media from the exponentially growing HepG2 culture.
Therefore clonogenic assay on HepG2 cells could not be performed.
2.5 Cell cycle analysis
For cell cycle analysis a BrdU-labeling protocol was used to identify cells in
S-phase of the cell cycle accurately. Cells were harvested from an exponentially
growing culture as described for other experiments and seeded in 6-well plates,
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approximately 150,000 cells per well.

After 24-hours adherent sub-confluent

monolayers were noted and cells were exposed to various experimental conditions.
At the end of the treatments, cells were washed and sampled at various time points
to study the progression of the cell cycle in time. One hour before each time point,
cells were pulsed with BrdU (10µM) for 1 hour. BrdU gets incorporated in the DNA
of cells in S-phase along with other nucleotides and can be detected using a mouse
FITC conjugated anti-BrdU antibody. A BrdU Flow Kit (BD Pharmingen, San Diego,
CA) was used according to the supplied instructions without modifications. For
counterstaining of DNA content, cells were incubated with 7-amino-actinomycin D
(7-AAD) supplied with the kit, on ice for 20 minutes before analysis on a BD LSR II
flowcytometer (BD biosciences San Jose, CA).
Single cell populations were identified using forward and side-scatter profiles.
A total of 10,000 events were recorded from a gated single cell population. For 7AAD fluorescence measurements, SORP YG laser (561nm) was used to excite the
cells and emission was recorded through a 630LP filter followed by a 660/20 filter.
For FITC fluorescence measurements, SORP blue laser (488nm) was used to
excite the cells and emission was recorded through 505LP filter followed by a
525/50 filter. There was no spectral over-lap between the two emission spectra and
compensation was not required. Data was analyzed using FlowJo 7.63 (Tree Star,
Inc., Ashland, OR)
2.6 Mouse model of hepatocellular carcinoma
For in vivo studies, an implanted mouse model of human HCC was
generated in CB17SCID mice (Taconic Hudson, NY). Female mice between 4-5
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weeks in age were purchased and acclimatized in M.D. Anderson Animal facilities
for up to 1 week. All animals were handled, housed and studied in accordance with
Institutional Animal Care and Use Committee.
Cultured luciferase and GFP-expression human HCC cell lines (Hep3B and
HepG2) were harvested from an exponentially growing culture and washed with
PBS. The cells were re-suspended in 3ml PBS and final centrifugation was
performed at 1000 RPM for 5 minutes. Supernatant was discarded and the cell
pellet was used for implantation. The concentration of cells achieved using this
protocol was 160,000 cells per micro liter. The cells were kept on ice and animals
were injected within 3-4 hours after final centrifugation.
Before surgery hair was removed from the ventral surface of the abdomen
using clippers. Mice were anesthetized using 2.5% isoflurane. The surgical field was
sterilized with 70% (v/v) ethanol in water. Mice were placed supine on a heating pad
and the surgical site was sterilized using povidone iodine swab sticks. After
confirming induction of anesthesia, an approximately 1-cm transverse incision was
made in the skin of the upper abdomen slightly left of the midline. Deeper layers of
muscle and peritoneum were incised and hemostasis was achieved using silver
nitrate chemical cautery sticks. By applying gentle pressure on the lower abdomen
and lower chest, the left lobe of the liver was eviscerated. A 10μl volume of cells
was aspirated (~1.6 million cells) using a Hamilton syringe with an angled 30guage-needle tip (point style 4, 30o, Hamilton Company, Reno, NV). The needle
was advance ~5mm in to the liver parenchyma of the left lobe and the cells were
gently deposited ~2mm underneath the liver capsule such that a bleb of fluid was
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observed. The needle was carefully withdrawn and the needle track was
immediately compressed with a sterilized cotton Q-tip for ~60seconds. A dab of
silver nitrate cautery or super glue was used to ensure hemostasis at the needle
site. The liver was returned to the peritoneal cavity. Peritoneum, abdomen and skin
were closed in a single layer using stainless steel surgical clips (Harvard Apparatus,
Holliston, MA). After surgery the mice were allowed to regain consciousness under
a thermal lamp and observed for 30-60 minutes before returning them to the
housing. Staples were removed 10-14 days after surgery.
Three weeks after implantation of tumor cells in the liver, bioluminescence
measurements were performed. D-Luciferin from firefly (Caliper Life Sciences,
Hopkinton, MA) was administered at a dose of 150mg/kg in 100μl intra-peritoneally
(i.p.). Animals were anesthetized using 2.5% isoflurane and imaged using Xenogen
IVIS-200 (Caliper Life Sciences, Hopkinton, MA) 5 minutes after the injection. The
imaging was performed over 2 minutes with a 1x1 binning. Mice that had any
bioluminescence activity above background (suggesting the development of tumors)
were included in the subsequent study. Based on bioluminescence ~95-99% of
mice develop tumors 3 weeks after implantation of cells for both tumor models.
While bioluminescence imaging was useful in determining the presence of tumors
before the start of the study, the levels of bioluminescence did not correlate with the
size of the tumors and hence could not be used to track the growth of tumors during
the study.
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2.7 Radiofrequency generator setup
A Kanzius non-invasive external RF generator (ThermMed, LLC, Erie, PA)
was used for animal hyperthermia exposures. The use of this generator has been
described previously (86). The generator operates at an adjustable output power (02kW) at a fixed frequency, 13.56 MHz. The generator is connected to a high Q
coupling system with a Tx head (focused end-fired antenna circuit) and reciprocal
Rx head (as a return for the generator) mounted on a swivel bracket allowing the
RF field to be oriented in either a horizontal or vertical direction (Figure 1). The two
heads were set at a distance of 3.5 inches apart. The Tx head is covered with a
Teflon plate whereas the Rx head has a conducting copper surface to allow
grounding of the animals as described later. The coaxial end-fire circuit in the Tx
head produces a uniform RF electric field up to 15cm in diameter.

The field

generated is predominantly electric with minimal magnetic component. We have
attempted to measure this electric field previously using a Hewlett Packard
Spectrum Analyzer (model 8566B, Agilent, Santa Clara, CA), an isotropic field
monitor and a probe (models FM2004 and FP2000, Amplifier Research Inc.,
Souderton, PA). However, at high power output (>100W) accurate measurements
cannot be performed because of heating of the measurement probe itself.
For animal RF field exposures, mice were anesthetized with a cocktail of
ketamine (100 mg/kg i.p.) and xyalzine (10 mg/kg i.p.). Hairs were removed from
the anterior abdominal wall using clippers. Before administering RF exposures,
certain steps were taken to ensure prevention of electrothermal injury. For instance,
mice that urinate in the RF field suffer severe burns in the groin region. This is
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because urine with high ionic content heats significantly faster than the mouse in an
RF-field. By gently pressing on the lower abdomen of the mouse, urine was
removed from the bladder before RF exposures. Parts of mouse’s body with pointed
geometry (paws, limbs, ears, whiskers and tail) accumulate a very high charge at
the tips because of an impedance mismatch. As a result mice can suffer intense
electrothermal burns at these sites. The experiments were therefore performed after
grounding all parts of the mouse’s body using a copper tape. A window was created
within the copper tape grounding-shield to allow RF exposure to the abdomen
(Figure 1). All experiments were performed for a 10-minute duration at 600W power
output to be consistent with prior reports in the literature (86).
2.8 Thermal imaging and fiber optic thermography
During RF-field exposure temperature from the abdominal surface of mice
was recorded using an infrared thermal camera (FLIR SC 6000, FLIR Systems, Inc.,
Boston, MA). This non-invasive measurement was performed for all mice to ensure
that the surface temperature did not exceed 43oC.
For liver and orthotopic xenograft measurements fiber optic thermography
was employed. Fluotemp, a fiber-optic probe (PhotonControl, Burnaby, BC,
Canada), 400 microns in diameter with a scientific accuracy of 0.1±oC was
advanced over a 20G, 1-inch needle. The needle was placed in the liver or liver
tumor under ultrasound guidance and the probe was advanced into the target
organ. Subsequently, the needle was retracted over the fiber-optic probe. This
probe was pre-tested for lack of heating in the RF field.
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Figure 1. Radiofrequency generator and fiber optic probe placement
Pane A. For fiberoptic thermography, a temperature-sensing probe is placed over a
20G needle. The needle is advanced into the tumor (T) under ultrasound guidance.
The probe is then advanced over the needle and the needle is withdrawn.
Pane B. Kanzius 13.56 MHz external RF generator system is shown (black box)
that is connected to an end-firing antenna in the transmission head (Tx). A spacing
of 3.5 inches exists between the Tx head and the receiver head (Rx)/ ground plate.
Panel C. A CB17 SCID mouse is placed supine on the ground plate of the Rx head.
A copper shield made from copper tape is used to ground the mice and prevent
electrothermal injury. An abdominal window is created in the middle of the copper
shield to allow thermal exposures to the tumor.
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2.8 Immunohistochemistry
Tumor tissues harvested at the end of the experiment were fixed in 10%
buffered formalin (pH 7.0) for 24 hours and subsequently stored in 70% Ethanol
(v/v) before embedding them in paraffin. For immunohistochemistry 5-micron
sections were placed on a glass slide and tissue sections were de-paraffinized and
rehydrated. Antigen retrieval was performed in citrate buffer at pH 6.0. The slides
were placed in Tris-buffer (pH 8.0) before further processing.
For fluorescence immunohistochemistry, a protocol similar to that used for
immunocytochemistry (described above) was used with some modifications
described here. Tris-buffer was removed and tumor section was encircled using a
pap pen (Electron microscopy sciences, Hatfield, PA). For blocking 5% (w/v) BSA
and 3 % (v/v) NGS was used instead of 3% BSA and 1% NGS, respectively.
Imaging was performed as for immunocytochemistry.
For chromogen-based immunohistochemistry, cleaved caspase-3 (CC-3) and
LC3B protein were detected using a rabbit monoclonal antibody, and Ki67 was
detected using a mouse monoclonal antibody. Mouse antibody was detected using
mouse-on-mouse HRP-Polymer Kit

(BioCare Medical, Concord, CA). Rabbit

antibody was detected using EnVision+/ HRP, rabbit kit (Dako, Carpinteria, CA).
The staining was performed on a Dako automated stainer (Dako, Carpinteria, CA).
Primary antibody incubation was 30 minutes. The slides were counterstained with
hematoxylin and a cover slip was sealed in place. Images were acquired using a
multispectral scope (Olympus IX51 featuring a CRi Nuance camera, Hopkinton,
MA). Staining was quantified using inFormTM (CRI, Capillary Life Sciences,
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Hopkinton, MA), pattern recognition software that subjects multispectral data to
machine-learning algorithms for accurate quantification of staining.
2.9 Statistical Analyses
The data were plotted and analyzed in GraphPad Prism (version 5, La Jolla,
CA). For data with Gaussian distribution and when comparing two groups, Student’s
t-test was used. Multiple group data was analyzed using one-way analysis of
variance (ANOVA). Where necessary ad-hoc post-tests were performed and the
type of test used is reported with the results. For all inferential statistics a p-value
<0.05 was considered significant.
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3. Results
3.1 Effect of moderate hyperthermia on HRR-pathway proteins
To investigate the effects of moderate hyperthermia on HRR-pathway
proteins, we evaluated three cells lines with varying p53 status i.e. Hep3B (p53 -/-),
HepG2 (p53wt/wt) and SNU449 (p53mut/mut; A161T). Exponentially growing cells in
60mm plates were subjected to hyperthermia at 42.5oC for 2 hours in an incubator
with humidified air and 5% CO2. Protein expression levels were monitored before
thermal exposure, immediately after thermal exposure and then over-time at 1 hour,
4 hour and 24-hour intervals, in whole-cell lysates. The data are shown in Figure 2.
The data demonstrate that with moderate hyperthermia exposure, initially
there is mild degradation of PARP-1 for Hep3B cells, while there is little or no
change for HepG2 and SNU449 cell lines. At 24 hours, however, PARP-1 levels
tend to increase (~5-fold) compared to control levels more in HepG2 cells but not in
SNU449 or Hep3B cells. Levels of p53, NBS1, Rad50 and Rad51 do not change
with thermal exposure in any of the cell lines tested. Interestingly, we find that levels
of Mre11 gradually decline after heat shock in all cell lines to less than half of the
control levels at 24 hours. This finding is most pronounced for HepG2 cells. It has
been

previously

reported

that

BRCA2

is

an

important

target

of

heat

radiosensitization (83). We find that the effect of hyperthermia on BRCA2 levels was
cell line-dependent. The wt-p53, HepG2 cells and mutant-p53, SNU449 cells
demonstrated negligible changes in BRCA2 levels after thermal exposure, however
p53-null, Hep3B cells demonstrated a slight decrease in BRCA2 levels.
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Figure 2. Effect of moderate hyperthermia on HRR-pathway proteins
Three liver cancer cell lines with varying p53 status were subjected to hyperthermia
at 42.5oC for 2 hours and levels of proteins monitored over time. C= control, before
hyperthermia. (A) Immunoblots, (B) Quantification by densitometry.
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3.2 Localization of HRR-pathway proteins to gemcitabine-stalled replication
forks
We asked if hyperthermia impairs localization of HRR-pathway proteins to
gemcitabine-stalled replication forks. To address that question we first sought to
investigate γH2AX-p as a marker of stalled replication forks. Phosphorylation of γH2AX has been observed to occur in association with double-stranded DNA breaks
induced by ionizing radiation. Increasing evidence has accumulated since then,
demonstrating γ-H2AX phosphorylation to be a sensitive but non-specific marker of
a wide-variety of insults to the DNA. For instance, it has previously been reported
that γ-H2AX-p foci mark gemcitabine-stalled replication forks without occurrence of
dsDNA breaks. It is also known that hyperthermia can induce γ-H2AX foci without
detectable damage to the DNA. To evaluate if γ-H2AX foci localize to stalled
replication forks, Hep3B cells were pulsed with BrdU for 30 min prior to addition of
gemcitabine. We found that almost all γ-H2AX foci localize with BrdU foci confirming
its presence at stalled replication forks (Figure 3). Cells that were treated with
hyperthermia alone also demonstrated γ-H2AX foci. We find that these foci were
significantly fewer (p<0.001) than gemcitabine treated cells. Interestingly, γ-H2AX
foci were only found in cells positive for BrdU suggesting specificity for S-phase
(Figure 4). Combining hyperthermia immediately followed by gemcitabine treatment
did not further increase γ-H2AX foci compared to the gemcitabine alone group. This
suggests a common etiology to the origin of γ-H2AX foci with hyperthermia i.e.
stalled replication forks. Transient stalling of replication forks is known to occur with
hyperthermia based on prior reports (87). If this assumption is correct then
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hyperthermia induced- γ-H2AX foci should colocalize with single-stranded DNA that
arises as a result of a stalled replication forks. Using replication protein A (RPA) as
a marker of single-stranded DNA we found that γ-H2AX foci after hyperthermia
exclusively colocalize with RPA foci confirming the nature γ-H2AX phosphorylation
after hyperthermia, which was previously not known (Figure 5).
After establishing γ-H2AX foci as a marker of stalled replication forks, we
evaluated recruitment of downstream pathway proteins to these sites. We exposed
cells to mild hyperthermia at 42.5oC for 75 min followed immediately by a high
concentration of gemcitabine (10μg/ml). This concentration was chosen to induce
maximal stalling of replication forks and hence maximum number of γ-H2AX foci in
each cell. It has previously been reported that PARP1 serves as an initial sensor at
hydroxyurea-stalled replication forks and catalyzes poly-ADP ribosylation (PAR) at
these sites. Localization of PARP1 within the nucleus is diffuse and does not form
distinct foci. However, PAR residues can form foci that can be detected using a
specific antibody. We found that there was no correlation between PAR staining and
γ-H2AX foci (not shown). Furthermore, PAR staining was found to occur in most
untreated cells suggesting a high baseline level of PARylation of chromatin.
Stalled replication forks can cause uncoupling between the replication
machinery and the double-stranded DNA unwinding helicase. This stalling leads to
stretches of single-stranded DNA. Replication protein A (RPA) has a high affinity for
single stranded DNA and is important in recruitment of downstream HRR-pathway
proteins to stalled replication forks. We find that pre-treatment with hyperthermia
does not inhibit localization of RPA to the sites of stalled replication forks (Figure 5,
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8). Downstream, RPA recruits proteins of the Mre11-Rad50-Nbs1 (MRN) complex.
Localization of the MRN complex to stalled replication forks is essential for HRR.
Within this complex, Mre11 is the key effector with known 3’-5’ exonuclease as well
as 5’-3’ endonuclease activity. In particular, Mre11 nucleolytic activity allows loading
of Rad51 recombinase by processing DNA ends at stalled replication forks. We note
that pre-treatment with mild hyperthermia impairs localization of Mre11 to sites with
γ-H2AX foci (Figure 6, 8). This pre-treatment further leads to inhibition of Rad51
loading at stalled replication possibly because of inhibited end processing by Mre11
(Figure 7, 8).
These data demonstrate that hyperthermia alters localization of the HRRpathway proteins at sites of stalled replication forks. We identify Mre11 as a key
thermolabile target of hyperthermia.
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Figure 3. Gemcitabine-stalled replication forks are marked by γ-H2AX foci.
Panel A. Hep3B cells were exposed to hyperthermia and/ or gemcitabine and DNA
immediately upstream of stalled replication forks was labeled with BrdU.
Panel B. Distinct foci marking gemcitabine-stalled replication forks are detected by
anti-BrdU antibody. γ-H2AX foci colocalize at sites of stalled replication
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Figure 4. Hyperthermia-induced γ-H2AX foci are S-phase specific
Panel A. S-phase cells were marked using BrdU incorporation over a period of 4.5
hours immediately after hyperthermia
Panel B. It was noted that hyperthermia-induced γ-H2AX foci only occurred in cells
staining positive for BrdU (S-phase cells)
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Figure 5. Gemcitabine and hyperthermia-stalled replication forks recruit RPA
Panel A. Hep3B cells were exposed to hyperthermia and/ or gemcitabine
Panel B. RPA colocalizes with γ-H2AX foci in cells treated with gemcitabine,
hyperthermia or combination of the two treatments.
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Figure 6. Inhibition of Mre11 recruitment at gemcitabine-stalled replication
forks by hyperthermia
Panel A. Hep3B cells were exposed to hyperthermia and/ or gemcitabine
Panel B. Mre11 was recruited at gemcitabine-stalled replication forks. Cells treated
with hyperthermia or combination with gemcitabine demonstrated decreased
colocalization of Mre11 and γ-H2AX foci.
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Figure 7. Inhibition of Rad51 recruitment at gemcitabine-stalled replication
forks by hyperthermia
Panel A. Hep3B cells were exposed to hyperthermia and/ or gemcitabine
Panel B. Rad51 was recruited at gemcitabine-stalled replication forks. Cells treated
with hyperthermia or combination with gemcitabine demonstrated decreased
colocalization of Rad51 and γ-H2AX foci.
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Figure 8. Quantification of data presented in Figure 3-7
*p<0.05, **p<0.01, ns = not significant, N/A = not applicable i.e. Hyperthermia
treated cells is not detected as distinct foci and therefore correlation could not be
quantified.
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3.3 Cell cycle alterations
The data thus far suggest that hyperthermia can alter the expression levels
and localization of HRR-pathway proteins. Since stalled replication forks are
primarily repaired through recombination-mediated repair, we postulated that
hyperthermia would inhibit the repair of gemcitabine-stalled replication forks
delaying progression through the cell cycle.
To test this hypothesis, we exposed Hep3B cells to gemcitabine for 24 hours
(approximate doubling time of Hep3B cells) at a concentration of 1μM. This
concentration is comparable to the peak intracellular concentration achieved with
clinically used fixed-dose rate regimens (88). Since incorporation of gemcitabine
only occurs during S-phase, exposing Hep3B cells for 24 hours ensures
incorporation of gemcitabine in all cells. For the last 2 hours of incubation, cells
were or were not exposed to hyperthermia at 42.5oC. The cells were washed with
PBS and media was replaced to allow recovery of stalled replication forks. Cell
cycle progression was analyzed over time (Figure 9A).
We note that a 24-hour incubation with 1μM gemcitabine completely halts
progression of cells through the cell cycle by activating a G1/S checkpoint (Figure
9B). Once gemcitabine is removed, these cells resume DNA synthesis in 24 hours
in a synchronized manner suggesting gemcitabine-induced cell cycle arrest is
reversible at clinically relevant concentrations. Interestingly the delay caused by
hyperthermia in progression through early and mid S-phase was negligible. We
noted

however,

that

gemcitabine

followed

by

hyperthermia-treated

cells

demonstrate a much slower progression through late-S and G2/M phase compared
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to cells treated with gemcitabine alone. This delayed arrest in late-S and G2 phase
with normal progression through early and mid S-phase demonstrates the temporal
separation of replication and recombination and is further discussed later. We also
note that the effect of hyperthermia on repair of stalled replication forks is transient
(lasting a few hours) as most cells progress to G0/G1 phase of the cell cycle
eventually.
Consistent with prior observations, our data demonstrate a late-S/ G2 arrest
when cells are treated with moderate hyperthermia alone (89-92). Although several
reports have noted this observation, an explanation of underlying mechanisms has
been lacking. Here we find that the duration of G2 arrest is ~39-48 hours. This
matches the delay in progression of cells through late-S/ G2 phase after recovery
from gemcitabine-stalled replication forks. Since recombination repair predominantly
occurs in late-S/ G2 phase, hyperthermia alone may inhibit HRR required for
spontaneously arising stalled replication forks. Hence, the data provide a rational
explanation of G2 arrest occurring after hyperthermia.
Cancer cells that fail to resolve stalled replication forks demonstrate
persistent staining for γ-H2AX phosphorylation sites. We used this strategy to
evaluate if gemcitabine treatment followed by hyperthermia would demonstrate
persistence of γ-H2AX positive cells in comparison with gemcitabine treatment
alone. To test this hypothesis we treated Hep3B cells with gemcitabine (100nM) for
24 hours. For the last 2 hours, cells were treated with or without hyperthermia at
42.5oC. The media was then replaced and cells were allowed to recover from
gemcitabine-stalled replication forks. We note that when cells are treated with a
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combination of gemcitabine and hyperthermia, γ-H2AX positive cells persist for a
longer duration compared to hyperthermia alone or gemcitabine alone treated cells
(Figure 9D). Moreover, the resolution of γ-H2AX positivity coincides with the
progression of cell cycle observed in the previous experiment.
These experiments demonstrate that hyperthermia significantly alters cell
cycle progression by inhibiting post-replication recombination repair and resolution
of gemcitabine-stalled replication forks as observed by persistent γ-H2AX staining.
We also note that this inhibitory effect is transient lasting with a duration of 48 hours
after hyperthermia exposure.
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Figure 9. Hyperthermia inhibits post-replication recombination repair at
gemcitabine-stalled replication forks.
Panel A. Experimental scheme is presented
Panel B. Cell cycle progression was monitored using flowcytometry in Hep3B cells
before after release from gemcitabine-induced G1/S arrest.
Panel C. Median DNA content of Hep3B cells was quantified using flowcytometry
after treating them according to the design in Panel A. (*p<0.05)
Panel D. Hep3B cells were treated with gemcitabine +/- hyperthermia and cells
positive for γ-H2AX foci in confocal microscopy images were quantified. (*p<0.05)
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3.4 Clonogenic survival & viability
Next, we wanted to understand the consequences of pronounced cell cycle
alterations and inhibition of stalled replication fork repair by hyperthermia on
reproductive viability of cancer cells. Clonogenic assays were performed on null-p53
Hep3B cells and mutant-p53 SNU449 cells after one of two combinations of
hyperthermia and gemcitabine in comparison with hyperthermia alone or
gemcitabine alone. Of note, WT-p53 HepG2 cells failed to form colonies when
plated as single cells for clonogenic assay, precluding further analysis of these
cells.
In one combination regimen, Hep3B or SNU449 cells were exposed to
gemcitabine for 24 hours and were then subjected to hyperthermia for the final 2
hours at 42.5oC. In a different combination regimen Hep3B or SNU449 cells were
exposed to hyperthermia for 2 hours at 42.5oC followed by gemcitabine for 24
hours. The media was replaced at the end of exposures and the colonies were
counted after appropriate duration. Figure 10 demonstrates a dose-dependent
enhancement of gemcitabine toxicity by moderate hyperthermia in both SNU449
and Hep3B cells irrespective of the dose schedule used. Next we evaluated
clonogenic viability at a gemcitabine concentration of 5ng/ml and varied the duration
of hyperthermia (30min - 4 hours). The data demonstrate a thermal dose-dependent
enhancement in synergistic toxicity of gemcitabine and hyperthermia.
Prior studies conducted as a part of this thesis demonstrated that Mre11 is a
key thermolabile target of hyperthermia. We asked if inhibition of Mre11
exonuclease activity by a specific inhibitor, mirin, would result in similar
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enhancement of gemcitabine toxicity. The above experiments were repeated with
and without a sub-cytotoxic dose of mirin (25μM). We found that inhibition of Mre11
exonuclease

activity

by

mirin

significantly

enhanced

gemcitabine-induced

clonogenic cell death (Figure 11). Furthermore, addition of hyperthermia did not
further enhance this toxicity confirming that thermal enhancement of gemcitabine
toxicity is mediated through an Mre11-dependent pathway.
To rule out the possibility of off-target effects of mirin, we developed a partial
Mre11 knockdown (shMre11) Hep3B cell line. Hep3B cells with complete
knockdown of Mre11 expression were not stable in cell culture. These cells were
then treated with or without gemcitabine and with or without hyperthermia. The
results are compared to a cell line expressing a non-specific shRNA (shControl)
subjected to same experiments. Similar to the results obtained with mirin, we found
that shMre11 cell line was more sensitive to gemcitabine in comparison with
shControl cell line. Furthermore, thermal enhancement of gemcitabine toxicity was
noted for shControl cell line but not with shMre11 cell line.
These

data

strongly

implicate

an

Mre11-dependent

homologous

recombination repair pathway in thermal enhancement of gemcitabine-induced
cytotoxicity.
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Figure 10. Hyperthermia sensitizes hepatocellular carcinoma cells to
gemcitabine in a dose-dependent manner.
Panel A. Experimental scheme is presented
Panel B &D. Experimental design i, ii and iii were used.
Panel C &E. Experimental design iv was used.
*p<0.05
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Figure 11. Hyperthermia-induced gemcitabine sensitivity of hepatocellular
carcinoma cells is via a Mre11-dependent pathway
Panel A. Hep3B cells were treated with gemcitabine alone (Gem), hyperthermia +/gemcitabine (HT), Mirin +/- gemcitabine (Mirin) or Hyperthermia and Mirin +/gemcitabine (Mirin-HT). In all cases hyperthermia followed gemcitabine or mirin
exposure. *p<0.05
Panel B. Control (shControl) or Mre11 knockdown (shMre11) were treated with or
without gemcitabine followed by +/- hyperthermia. *p<0.05
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3.5 Animal model studies
Two animal models of human primary hepatocellular carcinoma were
developed using a wt-p53 HepG2 cell line or null-p53 Hep3B cell line in immunedeficient CB17 SCID mice. The cells were implanted in the liver to generate an
orthotopic tumor model as detailed in the methods. We noted that both xenografts
were locally aggressive, eroded (as opposed to invaded) the normal adjacent
mouse liver and had no distant or intra-hepatic metastasis or extension in non-liver
viscera. However, Hep3B xenografts were fast growing unlike the HepG2
xenografts. On histological analysis, both tumors appeared hyper-vascular with
areas of spontaneous necrosis (Figure 12). We observed larger aberrant vessels
with Hep3B xenografts, which were not seen with HepG2 xenografts. The xenograft
models closely mimicked non-metastatic human primary hepatocellular carcinoma
based on growth pattern, macroscopic and microscopic appearance.

Figure 12. Animal model characterization (next page)
Panel A. A Hep3B xenograft is seen in the left lobe of CB17 SCID mouse liver at the
time of necropsy.
Panel B. The development of luciferase expressing Hep3B or HepG2 xenografts
can be tracked using bioluminescence imaging.
Panel C-F. Histological analysis demonstrates that these xenografts mimic human
hepatocellular carcinoma based on growth pattern, hyper-vascularity, erosion and
spontaneous central necrosis.
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After establishing the tumor models, we evaluated if hyperthermia could be
successfully delivered to the tumor tissue using the 13.56 MHz non-invasive
Kanzius RF generator. For that purpose, we employed fiber-optic thermography to
measure the temperature of liver tumor and normal liver in anesthetized mice
subjected to RF field exposure for 10 min at 600W. Since fiberoptic thermography
requires placement of a fiber-optic (400 micron diameter) probe under ultrasound
guidance and is challenging for smaller tumors, we wanted to investigate if
abdominal surface temperature as measured by infrared thermal imaging correlated
with tumor temperature. This would allow us monitor thermal dose in real-time noninvasively for future experiments. The data are shown in figure 13.
After anesthesia and during placement of mice on the Rx head of the RF
generator, we noted a drop in core body and surface temperature. For consistency
we allowed the abdominal surface temperature to drop to 34oC before starting RF
exposures. During a 10-minute RF exposure we observed a duration-dependent
near-linear rise in Hep3B xenograft and normal liver temperature. Interestingly,
normal livers heated significantly less than Hep3B xenografts, suggesting, some
tumor

selective

heating

effect

of

RF-field

exposure.

Abdominal

surface

temperatures recorded during these experiments demonstrated a strong linear
correlation with tumor temperature (R2=0.99). Prior reports have demonstrated that
a 10-min RF exposure using the same parameters is safe with no detectable harm
to normal tissues (86). Here we demonstrate that the same RF exposure can be
used to deliver tumor selective hyperthermia to orthotopic liver tumors. However,
the underlying reason for tumor selective hyperthermia is not evident from these
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experiments. Thermal dose calculations as defined by cumulative equivalent
minutes at 43oC (CEM43) were performed using the average time-temperature plots
obtained from liver tumor and normal liver during a 10-minute RF exposure. We
note that CEM43 for liver tumor was ~80 fold higher than that of normal liver
(CEM43: 1401.6 vs. 17.5).
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Figure 13. Thermal dose quantification in Hep3B xenografts under RF field
exposure (13.56 MHz, 600W)
Panel A. Xenograft and abdominal surface temperatures were measured in realtime using fiber optic thermography and infrared thermography, respectively in
tumor-bearing mice
Panel B. Similar measurements were performed on the normal livers of non-tumorbearing mice.
Panel C. Data in Panel A and B are combined for comparative representation.
Abdominal surface temperature is the composite average from tumored and nontumor-bearing mice.
Panel D. Tumor and surface temperature from Panel A is plotted and was found to
correlate in a linear fashion.
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To determine the anti-tumor effect of hyperthermia alone or in combination
with gemcitabine we used the same set-up as described above and in the Methods
section. For the Hep3B orthotopic tumor model experiment, we allowed the tumors
to grow for three weeks after implantation before starting treatment. At three week
after implantation of cells, bioluminescence imaging was performed to confirm
presence of tumors. Mice that developed tumors were randomized to one of five
groups: Untreated, RF exposure alone, gemcitabine alone, gemcitabine followed 24
hours later by RF exposure, or RF exposure immediately followed by gemcitabine.
This experimental design is comparable to in vitro studies reported above. The
treatments were administered twice a week for 3 weeks for a total of 6 treatments.
Gemcitabine dose administered was 70mg/kg/dose or 150mg/kg/week. This is
approximately half the dose used in humans (1000mg/m2/week dose in a 1.7m
human equals ~300mg/kg/week dose in a mouse). Twenty-four hours after the last
treatment, mice were sacrificed and tumors were harvested, weighed and fixed in
formalin for downstream analysis (Figure 14). At the end of the experiment, we
noted that tumors in all treatment groups were significantly smaller and had a lower
tumor mass than untreated controls (p<0.05). On further analysis, we compared
tumor mass of gemcitabine treated tumors with that of tumors that received
combination therapy. We found that combination therapy was more effective than
gemcitabine alone based on tumor mass (p<0.01). Of note, there was no difference
in tumor mass when comparing groups that received a different schedule of
combination therapy. From these data we conclude that addition of hyperthermia
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using the radiofrequency field enhances gemcitabine-mediated anti-tumor effect in
Hep3B xenografts.
This experiment was repeated in the slow growing wt-p53 HepG2 xenograft
model with some modifications in the design (Figure 15). Tumor presence was
confirmed at 4 weeks instead of 3 weeks using bioluminescence imaging to allow
the tumors to grow to a larger size. Mice with tumors were then randomized to one
of five groups as detailed in the previous experiment. Treatments were performed
once a week for a duration of 3 weeks instead of twice a week, keeping in mind the
slow growing nature of these xenografts. Unlike Hep3B xenografts we found that
HepG2 xenografts treated with RF exposure alone were not significantly different
from untreated controls. However, gemcitabine-treated groups had significantly
smaller tumors compared to mice treated with RF exposure alone or not treated.
Similar to the Hep3B xenografts we found that addition of hyperthermia to
gemcitabine significantly enhanced the anti-tumor effect of gemcitabine in HepG2
xenografts. Again, as with Hep3B xenografts no difference was noted between the
two schedules of combination treatment tested.
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Figure 14. Efficacy of gemcitabine and RF combination therapy in mice
bearing Hep3B xenografts
Tumor weight, percent growth inhibition and macroscopic appearance are
represented in Panel A, B &C, respectively. (*p<0.05, ***p<0.001 vs. Gemcitabine)
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Figure 15. Efficacy of gemcitabine and RF combination therapy in mice
bearing HepG2 xenografts
Tumor weight, percent growth inhibition and macroscopic appearance are
represented in Panel A, B &C, respectively. (*p<0.05, ***p<0.001 vs. Gemcitabine)
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From the in vitro studies we have established that Mre11 is a key
thermolabile target that is important in the repair of gemcitabine-stalled replication
forks. Inhibition of Mre11 exonuclease using mirin resulted in significant
enhancement of gemcitabine cytotoxicity in the Hep3B cell line. Despite its weak
inhibitory effects we wanted to evaluate if this thermomimetic response to mirin
could be reproduced in an in vivo Hep3B xenograft model. For that purpose, 4
weeks after Hep3B cell implantation, mice bearing tumors were randomized to no
treatment, gemcitabine alone (35mg/kg/dose), mirin alone (50mg/kg/dose) or a
combination of gemcitabine and mirin. The treatment was repeated two times a
week for two weeks. Of note, the dose of gemcitabine was reduced to half of that
used in previous experiments to better demonstrate the synergistic interaction, if
any. The dose of mirin chosen for this experiment was the maximum dose that
could be dissolved in the maximum amount of DMSO that could be safely
administered to the mice. All the mice not treated with mirin also received DMSO.
The data shown in Figure 16 demonstrate that there were no statistically significant
differences among the various tumor groups. We do note however, that the mice
treated with the combination therapy had the lowest median tumor mass.
Interestingly, we noted a bimodal distribution of tumor mass in the combination,
which was not observed with other groups. The reason for this finding is not evident
from this experiment, as we do not have correlative pharmacokinetic and
pharmacodynamic data on mirin. With its weak inhibitory effects on Mre11, mirin is
an unsuitable compound for drug development. We hope to repeat this experiment
with more effective inhibitors of Mre11 in the future.
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Figure 16. Efficacy of gemcitabine and Mirin combination therapy in mice
bearing Hep3B xenografts
Tumor weight, percent growth inhibition and macroscopic appearance are
represented in Panel A, B &C, respectively.
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From these three animal experiments, we draw several important
conclusions. First, RF exposure alone has an anti-tumor effect in Hep3B xenografts
but not in HepG2 xenografts. Second, HepG2 xenografts are more sensitive to
gemcitabine compared to Hep3B xenografts. Third, combination therapy with
gemcitabine and RF hyperthermia was more effective than gemcitabine alone in
both tumor models. Fourth, the schedule of combination therapy did not have an
impact on anti-tumor efficacy for the two schedules tested in either tumor model.
Finally, mirin, a water-insoluble, weak inhibitor of Mre11 exonuclease activity
demonstrated some anti-tumor effect in combination with gemcitabine and no antitumor effect when used alone. However, better inhibitors and further investigation is
needed to develop Mre11 inhibition as a thermomimetic approach to enhance
gemcitabine toxicity.

3.6 Histological analysis of human HCC xenografts from mice
Tumor tissues from the first Hep3B xenograft experiment were harvested 24
hours after the last treatment and analyzed. We evaluated the autophagy marker
LC3B and apoptosis marker CC3-3 in various tumor tissues using colorimetric
immunohistochemistry (Figure 17). Although tumors in the combination groups
demonstrated more frequent CC-3 positive cells than tumors in other groups, the
overall frequency of apoptotic cells was rare. Since Hep3B xenografts lack p53
expression, and apoptosis is tightly regulated by p53, this observation is not
unexpected. We evaluated autophagy as a marker of cell death and noted that
tumors that received combination treatment had a pronounced increase in

63

Copyright © 2012 Mustafa Raoof. All rights reserved.

autophagy compared to tumors in other groups suggesting an important role in the
observed anti-tumor effect. When evaluating proliferation using an S-phase specific
marker, Ki67, we found an increase in staining. It seems contradictory to have
increased proliferation in tumors with smaller mass. We interpret this to represent in
situ synchronization of tumor cells in S-phase 24 hours after last dose of
gemcitabine consistent with in vitro cell cycle analysis data.
Next we evaluated localization of the HRR-pathway proteins Mre11 and
Rad51 to sites of stalled replication forks in tumors of mice in various groups.
Stalled replication forks were detected by labeling γ-H2AX foci (Figure 18,19, 20).
Consistent with in vitro data we observed decreased localization of the HRRpathway proteins to sites of stalled replication forks. In addition we also noted a
relatively higher proportion of γ-H2AX positive cells in tumors treated with the
combination of gemcitabine and RF exposure in comparison with tumors in
gemcitabine only group. We interpret this to represent the presence of persistently
stalled replication forks or DNA damage in these tumors. Finally we also noted an
increased aberrancy in the shape of nuclei in tumors treated with combination
therapy compared to those treated with gemcitabine alone. These nuclei were
irregular in shape and appeared fragmented suggestive of unrepaired DNA
damage.
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Figure 17. Immunohistochemical analysis for proliferation, apoptosis and
autophagy
(A) Markers for apoptosis (CC-3), proliferation (Ki67) and autophagy (LC3B) were
evaluated in Hep3B xenografts. Tumors treated with combination gemcitabine and
RF therapy demonstrated increased apoptosis and autophagy compared to
untreated, gemcitabine alone or RF alone controls. Increased proliferation (Ki67) in
gemcitabine-treated tumor groups may represent in situ synchronization of cells in
S-phase of the cell cycle. (B, C) Tumor tissue staining for CC-3 and LC3B was
quantified and median (Inter-quartile range) is represented. *p<0.05 Mann-Whitney
Test (non-parametric)
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Figure 18. Inhibition of Mre11 localization to stalled forks in vivo
Hep3B xenografts were evaluated for colocalization of γ-H2AX and Mre11 foci. As
shown RF exposure inhibits Mre11 localization to stalled replication forks.

67

Copyright © 2012 Mustafa Raoof. All rights reserved.

Figure 19. Inhibition of Rad51 localization to stalled forks in vivo
Hep3B xenografts were evaluated for colocalization of γ-H2AX and Rad51 foci. As
shown RF exposure inhibits Rad51 localization to stalled replication forks.
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Figure 20. RF exposure inhibits resolution of gemcitabine-induced DNA
damage in Hep3B xenografts
Panel A. Sites of DNA damage were evaluated using fluorescence
immunohistochemistry for γ-H2AX. Also note the increased nuclear fragmentation in
the DAPI channel for combination therapy groups.
Panel B. Tumors treated with combination therapy demonstrate significantly higher
γ-H2AX staining. *p<0.05, **p<0.01 vs. gemcitabine.
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4. DISCUSSION
Several findings of this study have important implications for rational drug
combinations and multi-modality treatment of hepatocellular carcinoma. First, we
demonstrate that the HRR-pathway is invaluable in the repair of gemcitabine-stalled
replication forks. Second, the synergy between gemcitabine and hyperthermia has
been previously reported. However, a mechanistic understanding has been lacking
and the data presented here provide a rational explanation for this synergy. Third,
we demonstrate that the relevant thermal dose necessary for such synergistic
interaction can be achieved in pre-clinical mouse models using a non-invasive
radiofrequency field generator in a tumor selective fashion. Finally, these data
provide an initial platform for further development of thermomimetic approaches to
circumvent gemcitabine chemoresistance in hepatocellular carcinoma. These
findings are discussed in more detail below.
Gemcitabine is the only nucleoside analogue with a potent activity in solid
tumors. Its unique self-potentiating mechanism (discussed in the introduction) is
thought to be important for this activity. Several pathways have been implicated in
chemoresistance of solid tumors to gemcitabine. However most of these involve
reduced conversion of pro-drug (gemcitabine) to active drug (gemcitabine triphosphate) leading to decreased incorporation of gemcitabine in the DNA. Our data
demonstrate that clinically achievable intracellular concentration (1 μM) was
sufficient to arrest cell cycle in hepatocellular carcinoma cells suggesting adequate
incorporation of gemcitabine in the DNA. Moreover, 24 hours after removal of
gemcitabine, these cells resumed their cell cycle. Therefore pathways to repair
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gemcitabine-stalled replication forks must exist and may contribute to drug
resistance.
We evaluated proteins of the HRR-pathway believed to be important in the
restart of hydroxyurea-stalled replication forks. We failed to demonstrate PAR
localization to these sites as observed by Bryant et al. when evaluating
hydroxyurea-stalled replication forks (66). We attribute this discrepancy to our
inability to detect PAR foci due to high baseline levels of PAR residues in the nuclei
of cancer cells. It may also reflect differences in the replication poison used
(gemcitabine vs. hydroxyurea) or differences in the cell lines investigated. However,
we find that RPA, Mre11 and Rad51 readily accumulate at sites of stalled replication
forks. These findings are consistent with prior reports (62, 66, 93). We find that
Mre11 knockdown cells or cells where mre11 exonuclease activity was inhibited by
mirin were more sensitive to gemcitabine than control cells demonstrating the
significance of this HRR-pathway protein in gemcitabine resistance. This result is
consistent with observations of Ewald et al. with their study on leukemia cell lines
(62).
After demonstrating HRR-pathway as a survival mechanism for cancer cells
treated with gemcitabine, we asked if the same mechanism may be involved in antitumor synergy of gemcitabine and hyperthermia. When evaluating HRR protein
levels after hyperthermia we noted that mild-moderate hyperthermia had a transient
effect on PARP1 levels. Similarly levels of Nbs1, Rad50, Rad51 and p53 were
minimally affected. We note partial degradation of BRCA2 in one cell line. However
partial degradation of Mre11 was consistently observed in all cell lines.
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Thermolability of Mre11 has been recently reported in a study where only 10 min at
42.5oC reduced Mre11 exonuclease function to 10% of untreated control (81). On
further analysis we found that Mre11 and downstream Rad51 failed to localize at
gemcitabine-stalled replication forks in cells pretreated with mild hyperthermia.
Assimilating these observations and those from Dynlacht et al. we attribute this
effect to thermal denaturation of Mre11.
We demonstrate that hyperthermia has no effect on emergence from G1/S
arrest in cells with gemcitabine-stalled replication forks. In fact these cells
progressed through early and mid-S phase without much delay. However, we noted
a prolonged passage through late S and G2 phase, which is characteristic for cells
deficient in post-replication recombination repair (94). When evaluating synergy of
gemcitabine and hyperthermia Vertees el al. noted a similar enhancement of cells
arrested in G2/M phase with combination therapy (89). This delay in recovery was
also observed with persistent γH2AX staining in our study. Ultimately, we find that
this inhibition of the Mre11-dependent HRR pathway by hyperthermia is responsible
for decreased clonogenic survival and cell death.
It is important to discuss thermal degradation of BRCA2 and its effects on
HRR of stalled replication forks because BRCA2 plays two essential roles at the
stalled replication forks. BRCA2 prevents excessive nucleolytic degradation of
stalled forks by Mre11, an effect associated with genomic instability (82). Therefore,
degradation of BRCA2 is expected to increase excision of gemcitabine by Mre11
and contribute to chemoresistance. Conversely, BRCA2 participates in Rad51
loading in HRR pathway (95). In this case, degradation of BRCA2 is expected to
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inhibit repair of gemcitabine-stalled replication forks and have the opposite effect.
Because of this paradoxical effect at stalled replication forks it is unlikely that
BRCA2 is responsible for thermal enhancement of gemcitabine toxicity as observed
here. These findings also imply that synergistic interaction between hyperthermia
and gemcitabine will ultimately depend on the relative effect on heat on BRCA2
compared to that on Mre11. For instance, thermal degradation of BRCA2 without
Mre11 inhibition may not only contribute to gemcitabine resistance but also genomic
instability as detailed in a report by Schlacher et al. (82). Conversely, tumors
already deficient in BRCA2 may be more susceptible to thermal sensitization of
gemcitabine therapy. This speculation is supported by findings of Ying et al. who
demonstrate BRCA2 deficient cells to be more susceptible to Mre11 inhibition (93).
These speculations however, need to be tested in future studies.
We deduce from the mechanism of action described in this study that
inhibition of HRR by hyperthermia will be most effective when cells recovering from
gemcitabine are passing through late S and G2 phase of the cell cycle. This
underscores the need to optimize the dosing schedule in future studies. From
animal experiments we find that the schedule where the two therapies were give in
quick succession was comparable to the schedule where hyperthermia was given
24 hours after gemcitabine. We explain these findings based on the duration of the
effect of hyperthermia on HRR that lasts 39-48 hours. Our study also helps explain
findings of Van Bree et al. who noted maximum synergistic effect 24-48 hours after
gemcitabine dose in a rhabdomyosarcoma model (90). Even though comparative
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cell cycle analysis was not provided in that study, we expect the cells to be in late S
or G2 phase 24-48 hours after gemcitabine dose based on our findings.
While our data suggest that passage of cells through late S/ G2 phase with
stalled replication forks increases tumor cell kill, the mechanism remains to be
elucidated. Vertees et al. reported apoptosis to be a significant mechanism from this
combination therapy (89). In our study we noted that apoptosis was increased in
tumors treated with combination therapy however, the occurrence of apoptosis was
infrequent. This may be due to the lack of p53 in our Hep3B tumor model. In
support of alternative mechanisms we noted increased nuclear fragmentation and
increased autophagy in tumors treated with combination therapy compared to
controls.

75

Copyright © 2012 Mustafa Raoof. All rights reserved.

5. Conclusion and future studies
From the findings of this study we conclude that the HRR pathway is
important in the repair of gemcitabine-stalled replication forks. Inhibition of the HRRpathway protein, Mre11, enhances the toxicity of gemcitabine in cancer cells in vitro
and in vivo. Thermal enhancement of anti-tumor effect of gemcitabine is mediated
through inhibition of Mre11-dependent HRR pathway by denaturation and
degradation of Mre11. Non-invasive RF field-induced tumor selective hyperthermia
in combination with gemcitabine is superior to either modality alone in orthotopic
mouse models of hepatocellular carcinoma.
Future studies already underway will build on these findings to develop a
non-invasive combined modality treatment for patients with hepatocellular
carcinoma. For translation of this modality to clinic, certain questions need to be
answered first. Specifically, our data strongly suggest Mre11 as a key enzyme
responsible for the excision of gemcitabine from stalled replication forks. To confirm
this hypothesis, exonuclease assays will be performed using purified Mre11. In
addition the effect of hyperthermia on the ability of Mre11 to excise gemcitabine will
also be investigated. Our data demonstrate that the effect of hyperthermia is cell
cycle phase-dependent with maximum effect in the late S and G2 phase. Further
studies will utilize this information to optimize temporal parameters for maximum
anti-tumor effects. The findings of the study indicate that the currently available
inhibitor of Mre11 is not suitable for clinical use. More potent inhibitors need to be
developed for a thermo-mimetic approach to cancer therapy. In addition, the effects
of hyperthermia on Mre11 can be further exploited by combination with other DNA
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damaging agents that activate the HRR-pathway such as other replication inhibitors
e.g. hydroxyurea, nucleoside analogues or double-strand break inducers including
platinum compounds, alkylating agents and topoisomerase inhibitors. Finally,
translation of this modality to the clinic will also require parallel development of the
non-invasive RF generator hyperthermia system. We are currently performing large
animal studies to evaluate the safety and efficacy of this system before use in
humans.
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